Estimating Respiratory Syncytial Virus-associated Hospitalization in the First Year of Life Among Infants Born at 32-35 Weeks of Gestation

摘要

Background: Prophylaxis against respiratory syncytial virus-associated hospitalization (RSV-H) with anti-RSV monoclonal antibody is not considered cost-effective for routine use in most jurisdictions. The aim of this study was to develop a scoring tool to estimate local risk of RSV-H in the first year of life among moderately premature infants to assist in prophylaxis decision making.